Journal
ACS CHEMICAL NEUROSCIENCE
Volume 13, Issue 12, Pages 1697-1713Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.2c00172
Keywords
Alzheimer's disease; necroptosis; RIPK1; RIPK3; MLKL; therapy
Funding
- National Key R&D Program of China [2021YFA1302200]
- National Natural Science Foundation of China [82022065, 82073696, 81872791, U20A20136]
- Shanghai Shuguang Project [21SG038]
- Scientific and Technological Innovation Project of Shanghai [21S11900800]
- Key Research and Development Program of Ningxia [2019BFG02017, 2021BEG03103]
- West Light Foundation of the Chinese Academy of Sciences [XAB2020YW15]
Ask authors/readers for more resources
This article summarizes the potential role of necroptosis in Alzheimer's disease progression and explores the therapeutic capacity of targeting necroptosis for AD patients.
Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder featured by memory loss and cognitive default. However, there has been no effective therapeutic approach to prevent the development of AD and the available therapies are only to alleviate some symptoms with limited efficacy and severe side effects. Necroptosis is a new kind of cell death, being regarded as a genetically programmed and regulated pattern of necrosis. Increasing evidence reveals that necroptosis is tightly related to the occurrence and development of AD. This review aims to summarize the potential role of necroptosis in AD progression and the therapeutic capacity of targeting necroptosis for AD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
